Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2014

View Archived Issues

Neurotrope Bioscience licenses IP for Niemann-Pick Type C disease therapy

MorphoSys and Galapagos advance joint antibody program

Boehringer Ingelheim establishes a research alliance with the University of Toronto

HIV latency reversal achieved in patients with romidepsin

Camelid single-chain antibodies detect AD markers

ArmaGen forms strategic agreement with Shire to develop drug for Hunter syndrome

Phase II results presented for crenezumab for the treatment of AD

Wanbang completes first preclinical studies of SBM-TFC-039

Alios BioPharma's nucleoside analogue shows efficacy in phase II RSV study

Welichem terminates asset purchase agreement for WBI-1001

OncoSynergy reports novel anti-integrin beta1 MAbs

Enrollment complete in phase II trial of lirilumab in AML

Xoma discloses novel anti-FGFR-4 MAbs

EMA accepts MAA for asfotase alfa as a treatment for hypophosphatasia

Novel boron-containing beta-lactamase inhibitors disclosed by Rempex Pharmaceuticals

Incyte reports topline results from RELIEF trial of ruxolitinib

Researchers in Hungary and Switzerland design novel PLK1 inhibitors

Sarah Cannon Research UK and BioMarin collaborate on EMBRACA study

HPV immunotherapy VGX-3100 achieves phase II primary efficacy endpoint

Halozyme resumes enrollment and dosing in PEGPH-20 program

First vaccine candidate for malaria accepted for E.U. regulatory review

BioAlliance Pharma and Topotarget merger now legally effective

Nymox reports efficacy findings from repeat injection phase III study of NX-1207 for BPH

CTD Holdings closes private placement to advance Trappsol Cyclo

FDA accepts Sandoz's BLA for biosimilar filgrastim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026